Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 plus pembrolizumab versus chemotherapy plus pembrolizumab as first-line treatment for PD-L1-negative advanced or metastatic nonsquamous NSCLC
CTR20243435Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Oct 2024; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243435.